Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? | Zendy

Stephanie Chisholm | Zendy; Johan W. Mouton | Zendy; David A. Lewis | Zendy; T. Nichols | Zendy; C A Ison | Zendy; David M. Livermore | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

Author(s) -

Stephanie Chisholm,

Johan W. Mouton,

David A. Lewis,

T. Nichols,

C A Ison,

David M. Livermore

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq289

Subject(s) - cefixime , neisseria gonorrhoeae , cephalosporin , ceftriaxone , pharmacodynamics , medicine , microbiology and biotechnology , antibiotics , biology , pharmacokinetics

Gonorrhoea has been among the easiest infections to cure with antibiotics. Nevertheless, emerging resistance has driven repeated treatment shifts. Decreased cephalosporin susceptibility is now being reported. We examined cephalosporin MIC trends for Neisseria gonorrhoeae in the UK and undertook pharmacodynamic analyses to predict efficacy against strains with raised MICs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research